Figure 3.

Standard of care therapies for pulmonary adenocarcinoma cause transient and permanent changes in absolute lymphocyte and monocytes counts during therapy. From 22 pulmonary adenocarcinoma patients treated with at least three cycles of carboplatin-vinorelbine (A), automated leucocyte differential counts were retrospectively collected at two time points (at week 2 and week 3) during a 21-d cycle of chemotherapy. Weekly automated leucocyte differential counts were also collected from 23 patients treated with a 5-week cycle of radiotherapy (B). From all patients, counts were retrieved at baseline and post therapy. Results are presented as mean lymphocyte and monocyte counts (per 10⁹ cells) with SD. Wilcoxon signed rank test was used for statistical analysis (***p <0.001, **p < 0.01, *p < 0.05, NS = non-significant).